An exploration in pitfalls in interpreting SDHB immunohistochemistry
- 27 May 2022
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 81 (2) , 264-269
Abstract
Aims: Mutations and epimutations in genes encoding the succinate dehydrogenase complex (SDHx) are associated with multiple tumour types in which identification of SDH‐deficiency has significant management implications. Immunohistochemistry (IHC) for the succinate dehydrogenase B (SDHB) subunit can help to detect SDH‐deficiency, which manifests as complete loss of staining in tumour cells. However, a subset of SDH‐deficient tumours can show aberrant cytoplasmic SDHB‐IHC staining patterns and be misinterpreted as ‘retained’, a diagnostic pitfall complicating interpretation. Herein, we characterise in detail aberrant SDHB‐IHC staining patterns in SDH‐deficient tumours.Methods and results: We identified 23 tumours from patients with known germline SDHx and/or molecularly confirmed SDHx pathogenic/likely‐pathogenic variants in their tumour. Of these, eight (35%) showed significant SDHB‐IHC staining: one SDHA‐, one SDHB‐, three SDHC‐ and three SDHD‐mutated cases. In all eight cases, closer inspection revealed differences in intensity and intracellular distribution of SDHB‐IHC staining in tumour cells compared to adjacent non‐neoplastic cells: non‐neoplastic cells showed intense cytoplasmic coarse granular staining; tumour cells in seven of eight cases showed weak to focally strong, cytoplasmic blush to fine granular staining, in > 80% of cells. The remaining case in the initial block showed variably strong non‐granular cytoplasmic staining with globular perinuclear accentuation throughout, only subtly distinct from the staining pattern of non‐neoplastic cells. SDHB‐IHC performed on two additional blocks in this latter case revealed significant intratumoral heterogeneity, including convincing areas of complete loss.Conclusions: When evaluating SDHB‐IHC, care should be taken to distinguish true retained expression from aberrant cytoplasmic expression, which may be difficult to appreciate. Sometimes this may require additional molecular testing.Keywords
This publication has 23 references indexed in Scilit:
- Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinomaLaboratory Investigation, 2015
- Usefulness of Negative and Weak–Diffuse Pattern of SDHB Immunostaining in Assessment of SDH Mutations in Paragangliomas and PheochromocytomasEndocrine Pathology, 2013
- Succinate dehydrogenase (SDH) and mitochondrial driven neoplasiaPathology, 2012
- Succinate Dehydrogenase-Deficient GISTsAmerican Journal of Surgical Pathology, 2011
- Recent advances in the genetics of SDH-related paraganglioma and pheochromocytomaFamilial Cancer, 2010
- SDHB immunohistochemistry: a useful tool in the diagnosis of Carney–Stratakis and Carney triad gastrointestinal stromal tumorsLaboratory Investigation, 2010
- SDHA is a tumor suppressor gene causing paragangliomaHuman Molecular Genetics, 2010
- Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct TypesAmerican Journal of Surgical Pathology, 2010
- Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 CasesAmerican Journal of Surgical Pathology, 2010
- An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysisThe Lancet Oncology, 2009